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Even though many environmental and inherited predisposing factors have been associated 
with venous thromboembolism (VTE), still 30–50% of the events have no obvious provoking 
factors. There is limited knowledge concerning the association between endocrine-related 
factors and VTE risk. Therefore we aimed to investigate the relation between hyperglycemia, 
thyroid function, vitamin D, calcium, parathyroid hormone (PTH), and risk of future VTE in a 
general population. 
 Our study participants were recruited from the Tromsø study (Tromsø 4; 1994-95, 
Tromsø 5; 2001-2, and/or Tromsø 6; 2007-8). Two of the papers are based on all three 
surveys, one paper is based on the fourth and fifth, and one on the fourth survey only. The 
fourth survey is the largest one, and a total of 27 158 men and women attended. A subset of 
participants (n=9 056) were further invited to a more extensive second visit. In Tromsø 5 and 
6 only subgroups of the municipality of Tromsø were invited. The overall attendance rate 
went from 77% in Tromsø 4 to 66% in Tromsø 6. Incident VTE events were registered from 
the date of inclusion until the end of follow-up.  
 Our findings suggest that hyperglycemia does not play an important role in the 
pathogenesis of VTE, and that obesity is a more important contributor to VTE in subjects with 
hyperglycemia. TSH within the normal range were not associated with risk of VTE, whereas 
low and high TSH were associated with a moderately increased risk of VTE. However, the 
prevalence and the population attributable risk of thyroid dysfunction was low, suggesting 
that only a minor proportion of the VTE events in the population can be attributed to thyroid 
dysfunction. Vitamin D status was not associated with VTE risk. Finally, calcium and PTH 
alone were not associated with future risk of VTE. However, high levels of both calcium and 
PTH were associated with increased risk of VTE compared to subjects with normal calcium 




Flere ervervede og arvelige tilstedeværende faktorer har blitt assosiert med venøs 
tromboembolisme (VTE), likevel forekommer 30-50% av VTE-hendelsene uten kjent årsak. 
Det foreligger lite forskning på sammenhengen mellom endokrin-relaterte faktorer og risiko 
for VTE. Målet med denne avhandlingen var å undersøke sammenhengen mellom 
hyperglykemi, thyroideafunksjonen, vitamin D, kalsium, parathyroideahormon (PTH), og 
risiko for VTE i en generell befolkning. 
 Studiepopulasjonen vår ble rekruttert fra Tromsø-undersøkelsen (Tromsø 4; 1994-95, 
Tromsø 5; 2001-2, og/eller Tromsø 6; 2007-8). To av artiklene er basert på alle tre 
undersøkelsene, én artikkel er basert på den femte og sjette, og én er kun basert på den fjerde 
undersøkelsen. Den fjerde undersøkelsen er størst, og totalt 27 158 menn og kvinner deltok. 
En undergruppe av deltagere (n=9 056) ble også invitert til en mer omfattende 
spesialundersøkelse. I Tromsø 5 og 6 ble kun deler av Tromsøs befolkning invitert til å delta. 
Responsraten varierte fra 77% i Tromsø 4 til 66% i Tromsø 6. Førstegangs VTE-hendelser ble 
registrert fra inklusjonsdato og ut oppfølgingstiden.  
 Våre funn tyder på at hyperglykemi ikke spiller en viktig rolle i sykdomsutviklingen 
av VTE, men at fedme er en vesentlig bidragsyter for VTE hos personer med hyperglykemi. 
Serumnivå av TSH innenfor normalområdet var ikke assosiert med risiko for VTE, men lav 
og høy TSH var assosiert med en moderat forhøyet risiko for VTE. Dog var prevalensen og 
den tilskrivbare risikoen av thyroideaforstyrrelser i befolkningen lav, noe som tilsier at bare 
en liten del av risikoen for VTE i befolkningen skyldes thyroideaforstyrrelser. Vitamin D 
status var ikke assosiert med risiko for VTE. Videre var kalsium og PTH alene ikke assosiert 
med risiko for VTE, mens høye verdier av både kalsium og PTH økte risikoen for VTE 
sammenlignet med normale verdier.  
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Venous thromboembolism (VTE) is a collective term used to describe deep vein thrombosis 
(DVT) and pulmonary embolism (PE). DVT is the formation of a thrombus in the deep veins 
that prohibits normal venous blood flow back towards the heart. DVT primarily affects the 
large veins of the leg or thigh, but it can also occur in other parts of the body. The condition 
leads to pain, increased body temperature, discoloration and edema of the affected extremity. 
A PE is known as a potentially life-threatening complication of DVT, when an embolus 
dislodges from its original site and travels with the blood-stream to the arteries of the lungs. 
Where the vessel narrows, the clot is fixed and may obstruct the blood flow of the respective 
artery resulting in dyspnea, tachypnea and pleuritic chest pain1. However, without preexisting 
heart or lung disease, the signs and symptoms of a PE correlates with the extent of 
obstruction, and the clinical course ranges from asymptomatic to fatal circulatory collapse2. 
VTE is treated with anticoagulants, and the standard treatment has for many years consisted 
of an initial phase of concomitant low molecular weight heparin (LMWH) and a vitamin K 
antagonist (VKA), followed by VKA in monotherapy for the long-term treatment. However, 
direct oral anticoagulants (DOACs) are now implemented in the standard management of 
VTE, and these agents are recommended over VKA as long-term anticoagulant therapy in 
subjects with VTE and no cancer3. 
 
1.1 Epidemiology of venous thromboembolism  
 
VTE is the third most common cause of cardiovascular death in the Western world following 
myocardial infarction (MI) and ischemic stroke4. The incidence of VTE is 1 to 2 per 1000 
persons per year in Western countries, with a steep incline with age5-7. While the incidence of 
DVT and PE accounts for about two-thirds and one-third of the VTE cases, respectively2, the 
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two conditions are often present at the same time. Of those presenting with an acute DVT, 50-
80% have concurrent clinically silent PE8. Conversely, in about 50% of PE patients the source 
of the pulmonary emboli is unknown9-11. This could be explained by a complete evaporation 
or dislodging of the DVT. However, de novo pulmonary embolism should also be considered, 
possibly of cardiac origin12 or in relation to trauma13.  
A VTE event is classified as provoked or unprovoked (idiopathic), based on the 
presence or absence of provoking factors at the time of diagnosis. Provoked VTE events occur 
in the presence of transient risk factors (e.g. hospitalization, acute medical illness, surgery, 
trauma, plaster-cast and long-haul travel) or in the presence of more long-lasting conditions 
(e.g. active cancer, paralysis and wheel-chair use). A VTE event with no apparent risk factors 
present is classified as unprovoked. This classification is important in terms of risk of 
recurrence and treatment duration as the presence of transient factors (e.g. surgery) is 
associated with lower recurrence rates14-19 and justifies a shortened long-term treatment20, 
whereas VTEs provoked by a persistent factor (e.g. active cancer) have a high risk of 
recurrence15, 16, 18, 21, 22. Patients with unprovoked VTE have an intermediate- to high risk of 
recurrence14, 17-19, 23, 24. Population-based studies find that 50-60% of the VTE events are 
associated with provoking factors6, 25, 26. 
VTE is associated with serious short- and long-term complications. In about 25% of 
PE patients, the initial clinical presentation is sudden death5, and PE is estimated to be the 
leading preventable cause of death in hospitalized patients4. Furthermore, the overall mortality 
after a VTE event remains significantly increased up to eight years after the initial event27. Of 
patients presented with unprovoked VTE, 10-30% experience a recurrent VTE within 5 years 
despite adequate treatment16, 28, 29. Besides, patients initially diagnosed with DVT are more 
likely to develop a recurrent DVT rather than PE, and conversely, those who are initially 
diagnosed with PE are more likely to develop a recurrent PE30, 31. VTE is also associated with 
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the post-thrombotic syndrome (PTS) and pulmonary hypertension as a complication of PE8, 32. 
PTS occurs in 20-50% of the DVT patients, and the condition is characterized by chronic 
pain, edema, erythema, varicosities, paresthesias, and in more severe cases, leg ulcers and 
debilitating pain33. PTS is also associated with hampered quality of life and increased risk of 
disability pension34. Lastly, 3-5% among treated PE patients develop chronic pulmonary 
hypertension, which may result in disabling dyspnea, and shortened life expectancy due to 
progressive right ventricular failure35-37. 
Throughout the last decades, the diagnostics and treatment of VTE have been 
improved, but the incidence of VTE has not diminished38. In a cohort recruited from a general 
population, the incidence of VTE increased from 73 per 100,000 to 133 per 100,000 from 
1985 to 2009, primarily due to an increase in pulmonary embolism39. While the increase in 
VTE incidence may partially be explained by enhanced sensitivity of diagnostic methods, it 
may also imply that current prevention and treatment strategies are not optimal. As the 
European population is becoming older and more people develops cancer, the incidence of 
VTE is expected to increase even more. Further research is therefore needed in order to 
improve risk stratification, prevention and management of VTE, and thereby reduce the health 
related and economic burden associated with VTE. 
 
1.2 Pathophysiology of venous thromboembolism 
 
The hemostatic system is faced with the intricate task of keeping the blood circulating, while 
simultaneously converting blood into an insoluble mass at sites of vascular injury. However, 
hemostasis may cause severe disease if a too large insoluble blood mass is formed at wrong 
places, a pathological course termed thrombosis. The development of venous thrombi is 
according to Virchow’s triad (figure 1)40 a result of (i) changes in the blood composition (e.g. 
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hypercoagulability), (ii) stasis of the blood flow (i.e. changes in blood flow) and (iii) 
alterations of the vessel wall (endothelial activation or damage), and nearly all risk factors for 
VTE falls into one or more of these three groups. 
 
Figure 1. Virchow`s triad, illustrating the three most important factors contributing to venous thrombosis 
development. 
Alterations in the blood composition are crucial in venous thrombus formation, and a 
hypercoagulable state may be acquired or inherited. For instance, cancer patients have been 
shown to have increased plasma clotting factors and higher levels of TF compared to cancer-
free subjects41-43, suggesting an acquired hypercoagulable state in cancer patients. A 
hypercoagulable state can also be observed in pregnant women, where there is an acquired 
decrease in protein S followed by a substantial increase in levels of FVIII and FV44. Inherited 
hypercoagulability can be exemplified by inherited deficiency of antithrombin, a potent 
inhibitor of the intrinsic coagulation pathway by neutralizing the enzymatic activity of serine 
proteases such as thrombin, factor X and IXa45.  
Non-trauma related venous thrombus formation has been found to be a localized process 
primarily originating close to the vein wall in the deepest recess of the venous valve sinuses in 
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the calf-veins46. This concept is supported by the direct correlation between the frequency of 
DVT and the number of valves in individuals47. In the venous valve sinuses blood tends to 
linger48, assumingly due to stasis mediated through e.g. long-haul travel, advancing age, 
obesity and pregnancy. Severe hypoxia resulting from prolonged stasis has been documented 
at the level of the deepest recesses of the venous valve sinuses of dogs in the absence of calf 
muscle–driven pulsatile flow49. Furthermore, experimental studies have demonstrated a 
characteristic pattern of vortical blood flow within the valve sinuses during streamlined 
flow46, potentially explaining the severe hypoxia and thrombus formation observed in the 
deepest recess of the valve sinuses. As the innermost layer of the vessel wall is supplied from 
the vessel lumen, low oxygen tension caused by blood stasis leads to localized hypoxia. 
Hypoxia-related activation of endothelial cells lining the valve sinuses are shown to cause 
procoagulant responses such as increased levels of PAI-1 and vWF, as well as exposure of P-
selectin46, 50, 51, rendering the venous valve sinus prone to thrombus formation.  
Hemostasis is critical in the physiological management of vessel wall injury. However, the 
role of vascular injury have rarely been reported to cause venous thrombosis, apart from when 
it is associated with acute insults like surgery, trauma and the use of intravenous catheters52. 
In an autopsy study, Sevitt et al found no evidence of vein wall injury in 49 of 50 lower 
extremity thrombi, and the fibrin-rich regions attached the thrombi to the vessel wall, while 
the platelet-rich regions were localized further from the site of attachment53. These findings 
suggest that during the formation of a venous thrombi, activation of the coagulation system 
precedes the activation and aggregation of platelets53. This is in accordance to the greater 
effectiveness of anticoagulation as VTE prophylaxis than platelet inhibition. Finally, induced 
vessel wall injury is in experimental studies shown to be a poor stimulus to fibrin formation54. 
The surface of endothelial cells is covered by natural anticoagulants, such as endothelial 
protein C receptor (EPCR), tissue factor pathway inhibitor (TFPI), thrombomodulin and 
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heparin like proteoglycans50, 51, normally leaving the endothelial cells resistant to thrombosis. 
The concentration of these components is significantly higher in the microcirculation as the 
concentration of these factors is determined by the ratio of the endothelial cell surface to the 
blood volume55, and the efficacy of these natural anticoagulants strongly increases when the 
blood moves from the larger vessels to the microcirculation56, 57. Thus, the natural 
mechanisms controlling the coagulation in the large vessels are normally less effective. 
Moreover, both hypoxia caused by stasis, as well as vessel wall damage, may activate the 
venous endothelium in a procoagulant way. Granules containing vWF and membrane-bound 
P-selectin are released by activated endothelial cells and promote adhesion of leukocytes, 
platelets and TF- bearing microparticles (MP)51, 52. The tissue factor (TF)/factor VIIa complex 
is the primary physiological trigger of the so-called “extrinsic pathway” in the coagulation 




Figure 2. The figure depicts a 
venous segment near a venous 
valve. Oxygen tension may 
become particularly low in the 
pocket of the valve due to 
stasis and vortical flow 
pattern. This will result in 
activation of the venous 
endothelium, leading to the 
recruitment and binding of 
monocytes (Mc), platelets 
(Plt) and TF-positive 
microparticles (MP). 
Consequently, TF from 
activated monocytes and 
microparticles may activate 
the coagulation cascade and 




1.3 Risk factors of venous thromboembolism 
 
In epidemiology, a risk factor is generally any characteristic that increases the likelihood of 
developing a disease. VTE is a multifactorial disease, implying that several risk factors need 
to be present at the same time in order to induce thrombus formation 59. A dynamic, age-
dependent explanatory model for thrombosis risk has been suggested, wherein both hereditary 
and acquired factors associated with VTE risk interact 59. In this model, individual factors 
(e.g. high age and FV Leiden) alone may not be sufficient to cause VTE. However, by 
interacting with other provoking factors, such as surgery and immobilization, the joint effect 
of all risk factors may outweigh the natural anticoagulant properties, resulting in thrombosis 
(Figure 3).  
 
           
 
1.3.1 Hereditary risk factors  
 
Family history of VTE has been reported to provide a 2 to 3-fold higher risk of VTE60-64, and 
family studies have estimated that approximately 60% of the variation in susceptibility to 
thrombosis can be attributed to genetic risk factors65-67. Inherited thrombophilia generally 
increases VTE risk by two mechanisms59. The first group comprises the “loss of function” 
 
Figure 3. The thrombosis potential model. 
The blue line symbolizes a hereditary risk 
factor such as factor V Leiden (FVL), and 
the green line symbolizes the effect of age 
alone. The red line demonstrates the effect 
of both age and FVL, in combination with 
provoking factors early and late in life, 
respectively. The latter combination of both 
FVL, increased age and a provoking factor 
(e.g. surgery) is sufficient to exceed the 
thrombosis threshold.   
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disorders including deficiency of antithrombin, protein C and protein S. The prevalence of 
these deficiencies is rare (<1%)45, 68, nevertheless they increase VTE risk approximately 10-
fold45. The second group covers the “gain of function” disorders such as factor V Leiden 
(FVL), prothrombin G20210A and non-O blood groups. These disorders are less 
thrombogenic. However, they are far more common than the deficiencies of group one69. The 
FVL mutation, yielding a 3-fold increased risk of VTE through resistance to the anticoagulant 
function of activated protein C70, is present in about 5% of Caucasians in its heterozygous 
form45. Prothrombin G20210A is a polymorphism associated with increased prothrombin 
concentration. The prevalence is about 2% in the general population, and carriers with this 
polymorphism have 3-fold increased risk of VTE45, 71. However, the occurrence of FVL and 
Prothrombin G20210A varies with ethnicity and are more prevalent among whites than 
among patients with African or Asian descent72. The Non-O blood groups yields a 1.5-fold 
increased risk of VTE70, 73, and the association is partially explained by increased von 
Willebrand Factor (vWF) and FVIII74. However, the Non-O blood groups remains 
significantly associated with VTE after adjusting for both factors75, 76, implying that additional 
unknown pathways may contribute to the thrombotic risk among subjects with non-O blood. 
Inherited risk factors may be modified by the presence of other genetic or 
environmental factors, and this is known as gene-gene or gene-environment interactions. For 
instance, the co-inheritance of FVL and prothrombin 20210A polymorphism has been 
reported to promote a 20-fold increase in VTE risk77. In regard to gene- environment 
interactions, there has been reported an additional risk of VTE in obese carriers of FVL 
compared to the non-obese carriers78, 79, and the finding was described as an interaction on an 
additive scale.  
Even though a significant amount of VTE events may be ascribed to genetic factors, a 
recent review reported that known thrombophilias identified so far only explain about 5% of 
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VTE heritability70. During the last decades the genome-wide association studies (GWAS) 
have identified an extensive amount of new genetic mutations that are frequent in the 
population (e.g. single nucleotide polymorphisms; SNPs), but they only have a modest effect 
on VTE risk45, 70. Ongoing and future whole-genome sequencing studies will hopefully 
identify novel genetic risk factors for VTE. 
 
1.3.2 Non-hereditary risk factors  
 
Advancing age is the strongest and most consistent risk factor for VTE, and the overall 
incidence of first symptomatic VTE is 1-2 per 1000 person years in the general population, 
increasing from 1 per 10 000 person years in the age-group 25-30 years to 5-8 per 1000 
person years in those above 75 years2, 6, 26, 80. The steep incline in VTE risk by age may be 
explained by a larger increase in levels of procoagulant factors (e.g. FVII, FVIII, FX and 
fibrinogen) in the elderly than in anticoagulant factors81. The increased VTE risk could also 
be explained by age-specific risk factors (e.g. reduced muscle strength, endothelial 
dysfunction, venous insufficiency, and frailty)46, 82. For instance, altered venous blood flow 
caused by (age-related) changes in compliance in the vein wall has been reported83, and 
consequently, altered venous blood could affect the frequency and duration of blood stasis in 
the microcirculation46, potentially leading to thrombus formation. 
The number of overweight and obese individuals in the population has increased 
dramatically in the past few decades, especially in Western countries, and the rising 
prevalence of obesity is a major public health concern. According to the WHO classification, 
more than a third of the world's population was in 2014 either overweight (defined as Body 
Mass Index (BMI) ≥25 kg/m²) or obese (BMI ≥30 kg/m²)84. Growing evidence has accrued 
for obesity as an important risk factor for VTE. A meta-analysis by Ageno and co-workers 
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reported an OR of 2.33 for VTE in obese subjects compared with normal weight subjects85, 
and the association became stronger as the BMI increased85, 86. Although BMI has been the 
most commonly used anthropometric measure to assess the association between obesity and 
VTE, the composition of body fat and muscle mass can differ highly among subjects with the 
same BMI. The Danish Diet, Cancer and Health (DCH) study showed that all anthropometric 
measures (body weight, BMI, waist circumference (WC), hip circumference and total body 
fat) were associated with risk of VTE87. Investigators of the Tromsø study did also find all 
measures of obesity to be associated with VTE risk, though WC identified most subjects at 
risk and was the strongest predictor of VTE88. Some studies have assessed the joint effect of 
obesity with other genetic or environmental risk factors for VTE (e.g. factor V Leiden, body 
height), and showed that for some combinations there is a synergistic effect79, 89. A number of 
potential mechanisms by which obesity increases the risk of VTE have been suggested. 
Several studies have shown that high BMI is associated with increased plasminogen activator 
inhibitor-1 (PAI-1), TF, fibrinogen and FVIII90-94, supporting a relationship between obesity 
and coagulation. Furthermore, leptin, a hormone produced mainly by adipocytes and 
consequently raised in obese subjects, is associated with increased thrombosis risk by 
promoting platelet aggregation and inducing TF expression95. Finally, abdominal obesity is 
associated with increased intra-abdominal pressure and reduced venous blood flow velocity 
due to resistance of venous backflow from the lower limbs96, 97, potentially increasing the 
chance of thrombus formation.  
Although the association between cancer and VTE was first noted by Bouillard in 182398, 
the most detailed early description was provided by Trousseau in 186599. Cancer is today 
recognized as one of the most important risk factors for VTE. About 20% of all first VTE-
events are associated with cancer100, 101, and the overall VTE risk is estimated to be 4 to 7-fold 
higher in cancer patients compared to cancer-free subjects16. However, the VTE risk among 
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cancer patients varies highly according to cancer type, stage of disease, and treatment 
modality102. Brain and pancreas cancers are associated with the highest VTE risk, whereas 
prostate and breast cancers have generally been associated with a low VTE risk102. Several 
pathogenic mechanisms may promote thrombus formation in cancer patients including tumor 
induced platelet activation, enhanced expression of TF, reduced clearance of coagulation 
factors and decreased anticoagulant synthesis103. Furthermore, stasis induced by prolonged 
bed rest and/or vascular invasion by tumor may lead to thrombosis104, and moreover, patients 
with active cancer are more exposed to major surgery, chemotherapy, infections and 
hospitalization which all increase VTE risk. 
Hospitalization is another important risk factor for VTE100, 105. Hospitalized patients are 
often exposed to many risk factors for VTE (e.g. surgery, trauma, intravenous catheters, 
immobilization, pregnancy and chronic and acute medical conditions) at the same time106, 107. 
A nested case-control study showed that nearly 60% of all incident VTE events were 
attributed to institutionalization wherein hospitalization with surgery counted for 24%, other 
medical diseases for 22% and nursing home residence for 13%100. In a case-control study, 
recent hospitalization with and without surgery were associated with a 22 and 8-fold increased 
risk of VTE, respectively105. A recent meta-analysis has shown that anticoagulant prophylaxis 
reduces the risk of non-fatal PE and symptomatic DVT by 39% and 53% in non-surgical 
patients, respectively108. Nonetheless, according to a systematic review, only 11-19% of 
hospitalized patients received appropriate anticoagulant prophylaxis109. The Padua Prediction 
Score for Risk of VTE have been developed in order to identify patients with acute medical 
conditions that are admitted to hospital and whom may benefit from VTE prophylaxis110. The 
score encompasses almost every potential risk factor for VTE, and it provides a fairly simple 
score of 11 parameters, by which clinicians can stratify their patients according to a VTE 
prophylaxis threshold. Barbar et al found that 40% of consecutive patients admitted to an 
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internal medicine department were classified to have high risk of VTE (i.e. Padua Prediction 
Score ≥ 4), and the VTE risk was 87% lower in high risk patients who received 
anticoagulation than those who did not110. International guidelines strongly recommend that 
patients with high risk of VTE according to the PADUA Prediction Score receive 
anticoagulant thromboprophylaxis unless the risk of bleeding complications are too high108. 
Furthermore, the PADUA model provided the best available basis for judging the VTE risk in 
hospitalized medical patients108. 
Immobilization is an established risk factor for VTE. A meta-analysis has shown that  
immobilization among medical bedridden patients increases VTE risk by 2-fold111. However, 
the separate impact of immobilization among bed-rest patients could be difficult to estimate as 
this group could suffer from other underlying causes that may contribute to venous 
thrombosis. Nevertheless, an interrelation between immobilization and VTE is further 
supported by a meta-analysis where all-type travel was associated with a nearly 3-fold 
increased risk of VTE, and the VTE risk increased in a dose–response manner by 18% per 
each 2-hour increase in travel duration112. Several studies have also shown an increased risk 
for VTE in patients suffering from a stroke113-115. The predisposition to thrombosis in 
immobilized subjects may be caused by stasis due to a supine position that prohibits muscle 
pump activity. Additionally, muscle mass may decrease during bed-rest and could even after 
the period of prolonged immobility cause inadequate venous emptying. 
Pregnancy is acknowledged as a risk factor for VTE, and pulmonary embolism is 
shown to be the leading cause of maternal death in the developed world116. In observational 
studies, pregnant women have a 4 to 5-fold higher risk of VTE compared to non-pregnant 
women, and in the post-partum period the VTE risk is 20 to 80-fold higher38, 117. Furthermore, 
the risk of pregnancy-associated VTE is increased by 52 and 31-fold in carriers of factor V 
Leiden and the prothrombin 20210A mutation, respectively, compared with non-pregnant 
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women without the mutation117. A hormone-induced shift in pregnant women increases levels 
of clotting factors and reduces fibrinolytic activity, probably to prevent fatal bleeding 
complications during delivery118. Furthermore, increased venous capacitance and reduced 
venous outflow in pregnant women, along with mechanical obstruction by the uterus, may 
contribute to pregnancy-associated thrombosis119. 
Growing evidence points to a bidirectional relationship between VTE and arterial 
cardiovascular diseases (CVD) (e.g. myocardial infarction (MI) and ischemic stroke)120-128. 
The association between arterial CVD and VTE could be attributed to shared risk factors, 
indirect causal factors, or a direct causal relationship129. Additionally, atherosclerosis may 
potentially initiate both venous and arterial thrombosis, however results concerning the 
association between atherosclerosis and VTE are diverging130-133. Prospective cohorts 
applying cause-specific regression models, have shown that of traditional atherosclerotic risk 
factors, only age, obesity and a family history of MI are shared risk factors for arterial CVD 
and VTE26, 134-136. Moreover, observational studies have demonstrated a transient association 
between MI, stroke and future risk of VTE in the general population122-125, and the risk 
estimates were higher for provoked VTE, suggesting that indirect causal factors (e.g. 
hospitalization and subsequent immobilization) may contribute substantially to the observed 
association between MI, stroke and incident VTE124, 125. Nevertheless, direct causal 
mechanism(s) secondary to local disturbances in the cardiopulmonary circulation or 
electromechanical pathway (e.g. atrial fibrillation) may also contribute to the VTE risk 
observed in MI patients124. In the recent years, there have also been reported resemblances in 
the treatment between VTE and CVD. Rosuvastatin, a cholesterol-lowering drug, and 
acetylsalicylic acid, an antiplatelet drug, both used in the prevention of arterial CVD have 
been found to reduce the risk of VTE137, 138. 
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Despite the current knowledge of hereditary and non-hereditary risk factors for VTE, still 
30–50% of VTE events have no apparent provoking factor2, 25. Further research regarding risk 
factor management of VTE is therefore important. 
 
1.3.3  Endocrine-related risk factors 
Hormones regulate several organs and body functions. It is well known that current use of 
estrogens in terms of combined oral contraceptives (COC) and hormone replacement therapy 
(HRT) are associated with an increased risk of VTE139, and COCs and HRT are both used 
widely in developed countries. The risk of VTE has been shown to vary according to type and 
amount of estrogen and combined progestogen in COCs, as well as in the duration of use, and 
a 2 to 6-fold increase in VTE risk has been reported140. The third generation COCs (i.e. 
containing desogestrel or gestodene) yields the highest risk, and the risk is at its uppermost the 
first year of use140. In a meta-analysis, current users of postmenopausal HRT were found to 
have a 2 to 3-fold increased risk of VTE compared to non-users, and as for COC users the risk 
was highest during the first year of use141. Usage of COCs induces an increase of clotting 
factors (e.g. fibrinogen, prothrombin, FVII, FVIII and FX) and a decrease of anticoagulants 
(e.g. antithrombin, protein S and TFPI)142. Similar changes take place in women taking HRT, 
but in HRT users there has been suggested a threshold effect as changes in hemostatic factors 
were higher in women taking conventional high dose HRT as compared with low-dose 
therapy142. Furthermore, supra-physiologic estrogen administration to men has also been 
reported to provoke VTE143. Several studies advocate that other hormones also influence the 
hemostatic balance144, and some endocrine disorders (e.g. diabetes mellitus (DM), vitamin D 




1.3.3.1 Hyperglycemia and subsequent diabetes mellitus 
When blood glucose levels rise after a meal, insulin is secreted from islet of beta cells in the 
pancreas. Insulin activates uptake of glucose from the blood stream to insulin sensitive 
peripheral tissues. Insulin also stimulates the storage of glucose and suppresses the 
endogenous glucose production in the liver. In healthy individuals blood glucose levels are 
normalized within two hours after a meal, whereas in subjects with insufficient insulin 
secretion, hepatic or peripheral insulin resistance, blood glucose levels rise and may lead to 
hyperglycemia and subsequent DM145, 146. There are two distinct types of DM (i.e. DM type 1 
and 2). While DM type 1 is an autoimmune disease with a sudden loss of beta cells leading to 
life-long insulin treatment, DM type 2 is a metabolic disorder associated with insulin 
resistance and characterized by chronic and slowly progressing hyperglycemia and altered 
lipid metabolism146. During the last decades the prevalence of hyperglycemia has increased 
substantially throughout the world, and hyperglycemia along with subsequent DM has 
become a major public health problem. Experimental studies have suggested that 
hyperglycemia in different ways may facilitate thrombosis through activation of the 
coagulation system147, as well as by impaired fibrinolysis148. Both hyperglycemia and DM are 
well established risk factors for arterial CVD and all-cause mortality149, 150, and a consistent 
relationship between glycated hemoglobin (HbA1c) and arterial CVD151, 152 has been 
suggested. HbA1c is a marker of average plasma glucose in an individual over the preceding 
8 to 12 weeks153, and is recommended as a diagnostic test for DM with a cut-off at 6.5%154. 
Some observational studies have reported an increased risk of VTE in persons with 
hyperglycemia and/or DM80, 155-159, while other studies have failed to find an association135, 
160-165. A report from the Iowa Women`s Health Study155 found a 2-fold increased risk of VTE 
in women with self-reported DM, and in a case-control study158, hyperglycemia was 
associated with increased VTE risk independent of DM status. However, in a case-control 
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study by Heit et al160, the observed link between DM and VTE was explained by more 
frequent hospitalizations of persons with DM, and thereby being predisposed for VTE. The 
observed inconsistencies regarding the impact of hyperglycemia and DM on VTE risk may 
also rely on differences in study design (e.g. reversed causation in case-control studies), study 
population, the definition of hyperglycemia and DM (e.g. non-fasting or fasting glucose 
levels, HbA1c, self-reported DM or previous discharge diagnosis of DM), number of VTE 
events (power issues) and failure in adjustment for important confounders such as obesity. 
 
1.3.3.2 Thyroid function 
The thyroid is a small butterfly-shaped endocrine gland localized below the larynx in front of 
the trachea. The thyroid gland produces two thyroid hormones (i.e. Thyroxin and 
Triiodothyronine). The main task of the thyroid hormones is to regulate our body's 
metabolism, but they may also influence various physiological and pathological processes in 
the body166, 167. The pituitary gland, located at the base of the brain, controls the thyroid gland 
by producing thyroid-stimulating hormone (TSH). TSH induces the thyroid gland to produce 
more thyroid hormones in situations when the body needs to increase the metabolism, and 
TSH is usually considered the most sensitive measure of thyroid function168. Imbalances in 
the production of thyroid hormones usually arises from dysfunction of the thyroid gland itself 
and can result in hypothyroidism or hyperthyroidism. Hypothyroidism occurs when the 
thyroid gland is less active than normal producing insufficient amounts of thyroid hormones. 
The TSH levels are then elevated since the body wants to increase the production of thyroid 
hormones. Contrary, in subjects with hyperthyroidism the thyroid is too active and produces 
more thyroid hormones than the body needs. In this situation, the levels of TSH are decreased. 
Subjects with normal levels of thyroid hormones, though slightly increased or decreased 
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levels of TSH, are said to have subclinical hypothyroidism or subclinical hyperthyroidism, 
respectively169, 170. The prevalence of thyroid disorders is clearly increasing in the general 
population, and the world faces a burden of thyroid disease that has reached epidemic 
proportions. A hypercoagulable state has been linked to both hyperthyroidism171, 172 and 
subclinical- as well as overt moderate hypothyroidism173-175. Furthermore, a relationship 
between thyroid dysfunction and arterial CVD has been reported176, 177. Only four 
observational studies have investigated the association between thyroid function and risk of 
VTE178-181. A retrospective registry-based study reported a 1.6-fold increased risk of VTE in 
hypothyroid patients178, whereas no association was found in hyperthyroid patients. In 
contrast, a case-cohort study found a 2-fold increased risk of PE in hyperthyroid patients179. 
Furthermore,  a case-control and a nested case-control study have shown that even high 
normal levels of free thyroxin (FT4) increase the risk of VTE, whereas TSH levels are 
inversely and more moderately associated with VTE risk180, 181.  
 
1.3.3.3 Vitamin D 
Vitamin D was discovered in 1922 and due to its effect on bone metabolism it has for decades 
been used in prevention and treatment of rickets in children and osteoporosis in adults182, 183. 
Vitamin D is a fat soluble vitamin that exists in two forms; ergocalciferol (vitamin D2) and 
cholecalciferol (vitamin D3). Vitamin D acts like a pre-hormone as it is not biologically active 
until it has been converted by the liver to 25-hydroxyvitamin D (25(OH)D)183. In the kidneys 
25(OH)D is further converted to the more active form 1,25-dihydroxyvitamin D 
(1,25(OH)2D), and this step is regulated by serum ionized calcium and parathyroid hormone 
(PTH) levels183. However, serum levels of 25(OH)D is regarded as the biomarker of vitamin 
D status in individuals without kidney disease, as it is the substrate for the renal and non-renal 
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production of 1,25(OH)2D, has a longer biological half-life than 1,25(OH)2D and circulates in 
much higher concentrations184. The two sources of vitamin D are diet and sun exposure182, 
and serum 25(OH)D reflects the total production of vitamin D from both endogenous and 
exogenous sources, including sun exposure and intake of various dietary forms. Although the 
classic effect of vitamin D is regulation of calcium, phosphate and bone metabolism183, 
vitamin D receptors have a broad tissue distribution185, and serum 25(OH)D levels have been 
proposed to influence the risk of several common diseases that are not related to bone 
metabolism182. Several experimental and clinical studies have shown that vitamin D may 
promote antithrombotic effects186-188. Moreover, a prospective cohort study has reported an 
association between vitamin D insufficiency and risk of arterial CVD189. Regarding vitamin D 
and risk of VTE, only one study has been published reporting that women with active sun 
exposure habits have 30% lower risk of VTE compared to women with low sun exposure 
habits190, presumably mediated by higher vitamin D levels190.  
 
1.3.3.4 Calcium and parathyroid hormones 
Parathyroid disorders are among the most common endocrine disorders. Primary 
hyperparathyroidism, with an annual incidence of about 20 cases per 100 000, is the most 
frequent191. Primary hyperparathyroidism is caused by autonomous production of PTH by one 
or more of the four parathyroid glands localized on the back of the thyroid gland. PTH is a 
key hormone in calcium homeostasis with an inverse relation to ionized calcium under normal 
conditions. Low serum ionized calcium triggers the secretion of PTH from the parathyroid 
glands resulting in a rise in serum ionized calcium due to calcium mobilization from the 
bones, increased renal reabsorption and intestinal uptake of calcium via increased production 




Several experimental studies have shown a hypercoagulable state in patients with primary 
hyperparathyroidism and consequently chronic hypercalcemia193-195. Population based cohort 
studies have also demonstrated that serum calcium and PTH are independent risk factors for 
myocardial infarction in middle-aged men196 and arterial cardiovascular mortality in elderly 
men197, respectively. A randomized controlled trial (RCT) reported no effect on overall VTE 
risk by daily supplementation with calcium and vitamin D for 7 years in postmenopausal 
women, but they did observe an increased risk for unprovoked VTE198. To the best of our 
knowledge, no population-based study has investigated the associations between serum levels 














2. AIMS OF THE STUDY 
The aims of the study were: 
 
 To investigate the association between hyperglycemia, assessed according to HbA1c, 
and future risk of venous thromboembolism in a cohort recruited from a general 
population. 
 
 To examine the association between thyroid function, assessed by TSH, and future risk 
of VTE in a general adult population with repeated measures of TSH. 
 
 To assess whether serum levels of 25(OH)D were associated with risk of VTE in a 
large, prospective, population-based study.  
 
 To examine the relationship between serum levels of calcium and PTH, and the future 








3. STUDY POPULATION AND METHODS 
3.1 The Tromsø Study 
The Tromsø study is a single-centre prospective, population-based study with repeated health 
surveys of the inhabitants of the municipality of Tromsø, Norway199. It was originally 
initiated in 1974 as the Tromsø heart study in order to investigate and prevent arterial CVD. 
At that point of time it was a high cardiovascular mortality in North-Norway. Today, the 
Tromsø study has developed into being a large epidemiological study including a broad 
spectrum of diseases, and seven surveys have been conducted so far. All four papers of this 
thesis are based on data from the Tromsø Study (Tromsø 4; 1994-95, Tromsø 5; 2001-2, 
and/or Tromsø 6; 2007-8). Two of the papers are based on all three surveys, one paper is 
based on the fourth and fifth, and one on the fourth survey only. The fourth Tromsø survey is 
the largest one, and consisted of two screening visits with an interval of 4-12 weeks. All 
inhabitants aged >24 years where invited to the first screening visit, and a total of 27 158 
subjects took part. A subgroup (n=10 542) was further invited to the second screening visit 
that included blood samples for hormone analysis (e.g. vitamin D, TSH and PTH). In the fifth 
Tromsø survey, all men and women older than 29 years, living in the same area, and who 
participated in the second screening visit of the fourth Tromsø survey or became 30, 40, 45, 
50, or 75 years old during 2001, were invited to participate. A total of 8 130 men and women 
aged 30-89 attended the fifth survey. In the sixth Tromsø survey the following groups of the 
municipality of Tromsø were invited to participate; subjects who took part in the fourth 
survey; a 10% random sample of subjects aged 30-39 years; all individuals aged 40-42 years 
and 60-87 years and a 40% random sample of subjects aged 43-59 years. A total of 12 984 
men and women aged 30-87 attended the sixth survey. The overall attendance rate was high, 
ranging from 77% in the fourth Tromsø survey to 66% in the sixth Tromsø survey. The 
participants were followed from the date of enrollment through the end of the study period 
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(Paper 1 and 2; December 31, 2010, Paper 3; September 1, 2007, Paper 4; December 31, 
2012). 
 
3.1 Baseline measurements – (Tromsø IV, V and VI)  
In all three surveys baseline information was collected by physical examinations, blood 
samples, and self-administered questionnaires. Information on self-reported DM, history of 
arterial CVD (i.e. angina pectoris, myocardial infarction and stroke), current daily smoking, 
and physical activity (≥ 1 hour per week) during leisure time was collected from the 
questionnaires. The self-reported data of DM were supplemented with data on confirmed 
diagnoses of DM from the MI registry of the Tromsø Study. Height and weight were 
measured, and BMI was calculated as weight in kilograms divided by the square of height in 
meters (kg/m2). Blood pressure was recorded with an automatic device (Dinamap Vital Signs 
Monitor 1846; Critikon Inc., Tampa, FL, USA). Participants rested for 2 minutes in a sitting 
position before three readings were taken on the upper right arm at 2 minute intervals. The 
average of the two last readings was used in the analysis. Non-fasting blood samples were 
collected from an antecubital vein, serum prepared by centrifugation after 1 hour respite at 
room temperature, and further analyzed at the Department of Clinical Chemistry, University 
Hospital of North Norway. All samples were stored frozen at -70°C. Serum samples were 
analyzed for TSH with the AxSYM instrument (Abbott, IL, USA). In our laboratory, the 
reference range for serum TSH was 0.20–4.00 mIU/l. The Cobas Mira instrument was used to 
quantify HbA1c with an immunoturbidimetric method (Unimate 5 HbA1c, Hoffmann-La 
Roche). The reference range was 4.0% to 6.5%. Serum levels of 25(OH)D were measured in 
sera stored for a median of 13 years. 25(OH)D3 was determined by immunometry (ECLIA) 
using an automated clinical chemistry analyzer (Modular E170, Roche Diagnostics, 
Mannheim, Germany). The total analytical precision of the assay had a coefficient of variation 
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≤7.8% for any of three different concentrations (48.6, 73.8, and 177.0 nmol/l) according to the 
manufacturer. The manufacturer provides a population-based reference range of 27.7–107.0 
nmol/l for serum concentrations of 25(OH)D3 in adults. We revealed that this particular assay 
artificially measured 15–20% higher serum 25(OH)D levels in smokers than in non-smokers 
(14). The Hitachi Model 917 analyzer was used to quantify serum concentrations of calcium 
and creatinine with reagents from Boehringer Mannheim (Mannheim, FRG). The respective 
reference ranges were for serum calcium 2.15-2.51 mmol/L, and for serum creatinine 60-105 
μmol/L in men and 45-90 μmol/L in women. Creatinine values were used for estimation of 
the glomerular filtration rate (eGFR). eGFR was calculated using the recalibrated four-
variable Modification of Diet in Renal Disease (MDRD) study equation; eGFR = 175 × (s-
creatinine (μmol/l)/88.4)−1.154 × age-0.203 × (0.742 if female). Intact PTH was measured by 
an Immulite analyzer (Diagnostic Products, Los Angeles, CA, USA) on the basis of a two-site 
chemiluminescent immunometric assay. The reference range was 1.1-6.8 pmol/L for those 
below the age of 50, and 1.1-7.5 pmol/L for those 50 years and above. In the fourth Tromsø 
study serum calcium was analyzed within a week after sampling, whereas serum PTH was 
analyzed in 2001. Samples from the fifth Tromsø study were analyzed within 2 months for 
serum calcium and creatinine, and for serum PTH within 12 months. Serum total cholesterol 
and triglycerides were analyzed by enzymatic colorimetric methods and commercially 
available kits (CHOD-PAP for cholesterol and GPO-PAP for triglycerides: Boehringer-
Mannheim, Mannheim, Germany). Serum HDL cholesterol was measured after precipitation 






3.3 Outcome measurements 
 
3.3.1 Venous thromboembolism 
All first-time events of VTE during follow-up were identified by searching the hospital 
discharge diagnosis registry, the autopsy registry, and the radiology procedure registry of the 
University Hospital of North Norway. The University Hospital of North Norway is the only 
hospital in the Tromsø region, and all hospital care and relevant radiological procedures are 
offered here. The relevant discharge diagnosis codes were the International Classification of 
Diseases (ICD)-9 codes 325, 415.1, 451, 452, 453, 671.3, 671.4, 671.9 for the period 1994-
1998 and the ICD-10 codes I26, I80, I82, I67.6, O22.3, O22.5, O87.1 and O87.3 for the 
period 1999-2012. The hospital discharge diagnosis registry included diagnoses from 
outpatient clinic visits and hospitalizations. The radiology procedure registry was searched in 
order to identify potential cases of objectively confirmed VTE that may have been missed due 
to coding errors in the hospital discharge diagnosis registry. The medical record for each 
potential VTE case was reviewed by trained personnel who were blinded with regard to the 
baseline variables. A VTE event was only verified and recorded when all four of the 
following criteria were fulfilled; (i) objectively confirmed by diagnostic procedures 
(compression ultrasonography, venography, spiral computed tomography, perfusion-
ventilation scan or autopsy), (ii) the medical record indicated that a physician had made a 
diagnosis of DVT or PE, (iii) sign and symptoms consistent with DVT or PE were present and 
(iv) the patient underwent therapy with anticoagulants (heparin, warfarin, or a similar agent), 
thrombolytics or vascular surgery unless contraindications were specified in the medical 
record. VTE events deriving from the autopsy registry were recorded as outcomes when the 
autopsy record indicated VTE as a cause of death or as a significant condition contributing to 
death. Concurrent DVT and PE were registered as PE, and verified VTE events were 
classified as unprovoked or provoked based on the presence of provoking factors at the time 
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of diagnosis. A VTE event was defined as provoked if one or more of the following factors 
were present: surgery or trauma within 8 weeks prior to the event, acute medical conditions 
(e.g. acute MI, ischemic stroke or major infectious disease), active cancer at the time of the 
event, marked immobilization (i.e. bed rest for >3 days, wheelchair use, or long-distance 
travels ≥4 h within the last 14 days) or any other factor described by a physician in the 
medical record (e.g. intravascular catheter). 
 
3.3.2 Myocardial infarction, ischemic stroke and cancer 
In paper 4, subjects who developed MI, ischemic stroke or cancer were censored at the date of 
event in the cause-specific model. Cases of first-time MI and incident ischemic stroke were 
identified by linkage to the hospital discharge diagnosis registry at the University Hospital of 
North Norway (outpatient diagnoses included) and by searching the National Causes of Death 
Registry at Statistics Norway. Validation of MI and ischemic stroke were performed by an 
independently endpoint committee124, 125. Information on incident cancer during follow-up 










4.  MAIN RESULTS 
4.1 Paper I: 
HYPERGLYCEMIA, ASSESSED ACCORDING TO HBA1C, AND FUTURE RISK OF 
VENOUS THROMBOEMBOLISM: THE TROMSØ STUDY 
The aim of this study was to examine the association between hyperglycemia, assessed by 
HbA1c, and future risk of VTE in a general population. The Cobas Mira instrument was used 
to quantify HbA1c with an immunoturbidimetric method (Unimate 5 HbA1c, Hoffmann-La 
Roche). HbA1c was measured in 16 156 unique subjects (25-87 years) who participated in 
one or more surveys of the Tromsø study (Tromsø 4; 1994-95, Tromsø 5; 2001-2, and 
Tromsø 6; 2007-8). Incident VTE events were registered until December 31, 2010. Date of 
study enrollment for each individual was determined as the date of attendance in the first 
survey in which HbA1c measurements were available. Person-years were accrued from the 
date of enrollment through the date a VTE-event was first diagnosed, the date of migration or 
death or at the end of the study period. During a median of 7.1 years of follow-up, there were 
333 validated first VTE events. There was no increased risk of VTE per 1 standard deviation 
(SD) (0.7%) increase in HbA1c after adjustment for potential confounders. In the categorized 
analysis adjusted for age and sex, subjects with HbA1c ≥6.5% had 67% higher risk of VTE 
than subjects with HbA1c <5.7% (95% CI 1.01-2.74), and there was a significant linear trend 
for increased VTE risk across categories of HbA1c (P for trend 0.04). However, after 
adjustment for BMI, the risk estimates were attenuated and no longer statistically significant 
(HR 1.27; 95% CI 0.72-2.26, P for trend 0.27). Furthermore, subgroup analyses revealed a 
tendency of higher risk estimates for provoked than for unprovoked events in subjects with 
HbA1c ≥6.5% than those with HbA1c <5.7%. In conclusion, our findings suggest that 
hyperglycemia does not play an important role in the pathogenesis of VTE, and that obesity is 
a more important contributor to VTE in subjects with hyperglycemia. 
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4.2 Paper II: 
THYROID FUNCTION, ASSESSED BY THYROID STIMULATING HORMONE, AND 
FUTURE RISK OF VENOUS THROMBOEMBOLISM -THE TROMSØ STUDY 
This study was undertaken to investigate the association between thyroid function, assessed 
by TSH, and future risk of VTE in a general population with repeated measures of TSH. TSH 
was measured in serum samples from 11 962 subjects, aged 25-89 years, who participated in 
Tromsø 4-6, starting in 1994-95. The reference range for serum TSH in our laboratory was 
0.20–4.00 mIU/l. We used a time-varying analysis that allowed participants (n=3 035) who 
were re-measured in Tromsø 5 and Tromsø 6 to change (update) levels of TSH over time. 
Incident first-lifetime VTE were recorded through December 31, 2010. There were 289 
validated VTE events during a median follow-up of 8.2 years. Serum levels of TSH within the 
normal range were not associated with risk of VTE. In categorized analyses, low (prevalence: 
0.22%) and high (3.01%) TSH levels were associated with a moderate increase in VTE risk 
compared to normal TSH (multivariable HRs: 2.16, 95% CI 0.69-6.76 and 1.55, 95% CI 0.87-
2.77, respectively). In subgroup analyses, the association between the lowest (<0.05 mIU/L) 
and highest (>5.00 mIU/L) category of TSH and VTE only applied to provoked events 
(multivariable HRs 2.51, 95% CI 0.62-10.19 and 1.99, 95% CI 1.01-3.90, respectively). 
Subjects with thyroid dysfunction (i.e. after merging the lower and upper categories of TSH) 
had a statistically significant increased risk of provoked VTE compared to euthyroid subjects 
(multivariable HR 1.67, 95% CI 1.06-2.64). The overall population attributable risk (PAR%) 
for VTE by thyroid dysfunction was 4.4% (95% CI 1.0%-9.1%). In conclusion, thyroid 
dysfunction may predispose for VTE through associated hospitalization or co-morbidities. At 
the same time, the low prevalence of thyroid dysfunction and the low PAR%, suggest that 




4.3 Paper III: 
SERUM LEVELS OF VITAMIN D ARE NOT ASSOCIATED WITH FUTURE RISK OF 
VENOUS THROMBOEMBOLISM – THE TROMSØ STUDY 
The purpose of this study was to investigate whether high levels of 25(OH)D were associated 
with decreased risk of VTE in a prospective population-based study. Serum levels of 
25(OH)D were measured in 6 021 men and women, aged 25-84 years, who participated in the 
Tromsø Study in 1994-95. Incident VTE-events were registered from date of enrollment to 
the end of follow-up on September 1, 2007. During a median of 10.7 years of follow-up, there 
were 201 incident VTE events. The risk of VTE did not decrease per one SD (19.8nmol/L) 
increase in serum 25(OH)D (multivariable HR 1.02; 95% CI 0.91-1.22). Moreover, subjects 
with serum 25(OH)D ≥70 nmol/L (upper quartile) did not have decreased risk of VTE 
compared to those ≤44 nmol/L (lower quartile) in age- and sex-adjusted analysis (HR 0.91, 
95% CI: 0.60-1.37) or multivariable analysis adjusted for age, sex, BMI, smoking, and 
physical activity (HR 0.76, 95% CI: 0.45-1.28). Similar risk estimates across quartiles of 
serum 25(OH)D were found for unprovoked and provoked VTE. In conclusion, our findings 
suggest that vitamin D status does not play an important role in the pathogenesis of VTE.  
However, our findings did not apply to subjects with vitamin D deficiency (<30 nmol/L) due 







4.4 Paper IV:  
ASSOCIATIONS BETWEEN SERUM LEVELS OF CALCIUM, PARATHYROID 
HORMONE AND FUTURE RISK OF VENOUS THROMBOEMBOLISM -THE TROMSØ 
STUDY  
The aim of this study was to examine the relationship between serum levels of calcium and 
PTH, and the future risk of VTE in a general population with repeated measures of calcium 
and PTH. A total of 27 712 subjects (25-87 years) who participated in Tromsø 4 (1994-95) 
and/or Tromsø 5 (2001-02) were included in the study, and calcium and PTH were measured 
in 27 685 and 8 547 subjects, respectively. The reference range for calcium was 2.15-2.51 
mmol/L, and for PTH the reference range was 1.1-6.8 pmol/L and 1.1-7.5 pmol/L for those 
above and below the age of 50, respectively. A time-varying analysis was used allowing 
participants who were re-measured in Tromsø 5 (n=7 183) to change levels of calcium and 
PTH over time. Incident VTE was recorded through December 31, 2012. There were 712 
validated incident VTE events during a median follow-up of 15.0 years. Calcium and PTH 
were not associated with future risk of overall VTE, neither by a continuous nor by a 
categorical approach. Furthermore, in subgroup analyses, calcium and PTH showed no 
apparent association with unprovoked or provoked VTE, DVT or PE. However, subjects with 
the highest levels of both calcium and PTH (calcium ≥2.45mmol/L and PTH ≥4.0pmol/L) had 
increased risk of VTE compared to subjects with normal calcium and PTH (multivariable HRs 
1.78, 95% CI 1.12-2.84). In conclusion, our study showed that calcium and PTH were not 
associated with future risk of overall VTE. However, subjects with high levels of both 
calcium and PTH had increased risk of VTE. 
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5. GENEREAL DISCUSSION 
 
5.1 Methodological considerations 
 
5.1.1. Study design 
The data used in the present papers are all based on the Tromsø study, a large prospective 
cohort study of a general adult population. In a cohort study design, subjects are followed 
from the date of attendance until the occurrence of an outcome (e.g. disease) or until end of 
follow-up, making it possible to compare the rates of outcome between the exposed and non-
exposed subjects. In the present papers, incident VTE events during the study-period were 
registered, and absolute and relative risk estimates in terms of incidence rates and relative 
risks were obtained. In case-control studies individuals with an outcome of interest and 
matched controls without the outcome are included, and information about exposure is 
collected retrospectively in the same manner among cases and controls. Proportions of 
exposure among cases and controls are compared, providing only risk estimates in the form of 
odds ratios.  
A cohort study has several advantages compared to a case-control study. First, the 
clear temporal sequence of exposure and outcome in cohort studies is one of the Bradford Hill 
criteria for establishing causality201. In comparison, the retrospective nature of case-control 
studies makes it more prone to temporal bias (or reversed causality) as it cannot be definitely 
established whether the exposure preceded the disease of interest. Furthermore, recall bias 
could be present in case-control studies as cases and controls may remember and report 
information about exposure or outcome differently, and control selection may introduce bias 
if the chosen controls are unrepresentative of the reference population, especially in terms of 
exposure distribution. This is a particular problem when cases and controls are recruited 
exclusively from hospitals. Hospital patients tend to have different characteristics than the 
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general population, and if these characteristics are related to the exposure under investigation, 
the estimate of the association between exposure and disease will be biased. Although a 
cohort study is more likely to obtain valid and unbiased information on the subjects` exposure 
compared to a retrospective study, the exposures are not randomly assigned and factors 
influencing both the exposure and the outcome may be poorly quantified, lacking or 
unknown, potentially leading to residual confounding. Furthermore, when the exposure is 
modifiable and time between exposure assessment and disease manifestation is long (which is 
the case in all papers included in this thesis), some participants` individuals risk profile may 
change during follow-up, leading to regression dilution bias and an underestimation of the 
associations (see Modifiable factors). Thus, one cannot definitely establish whether the 
observed difference in outcomes between the two comparison groups is attributed to the 
exposure rather than other factors (confounders). In RCTs participants are allocated to 
intervention or control groups by chance, minimizing confounding. However, this study-
design has its disadvantages. Inclusion criteria’s for RCTs are often strict, and may cause 
selection bias and consequently reduce the external validity, rendering the cohort study the 
best alternative in many cases. RCTs are also time-consuming, expensive and sometimes 
ethically unfeasible. For instance, inducing hyperglycemia over a long time-period in order to 
investigate VTE risk would be ethically immoral when we are well aware of the harmful side 
effects of having high blood sugar. Another way to establish causality within observational 
studies, is by performing a Mendelian randomization study202. In this study, common genetic 
polymorphisms (i.e. alleles) that are associated with the modifiable exposure of interest (e.g. 
calcium and PTH) are randomly assigned, thus the risk of confounding is minimized, making 
this study design an efficient approach when dealing with modifiable exposures that are 
measured poorly and/or considerably confounded 203. However, the association between the 
genetic variant and the disease must be mediated through the exposure of interest, and suitable 
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genetic alleles to study particular exposures may not be available202. In paper 4, the 
Mendelian randomization approach could have been applied in order to investigate whether 
genetically raised serum levels of both calcium and PTH increases VTE risk, however no 
suitable genetic allele is available for this purpose.  
Another advantage of population-based cohort studies is the typically large number of 
study participants, enhancing the external validity and generalization of the study findings to 
the background population. Furthermore, cohorts are well suited to investigate rare exposures 
as entire populations are often invited to participate. However, a cohort design is an 
inefficient approach for examining rare diseases with long latency periods, as this is both 
time-consuming and requires a great number of participants. The design of a case-control 
study, including only subjects with a certain disease and eligible controls, is therefore more 
proper for investigating rare diseases than cohort studies. Case-control studies are also less 
time-consuming and less expensive than cohorts.  
   
5.1.2. Generalizability 
In a cohort study, eligible inclusion and exclusion criteria, a high participation rate and 
minimal loss to follow-up are crucial factors in order to obtain high external validity or 
generalizability of the study findings. All papers of this thesis are based on data from the 
Tromsø study (Tromsø 4; 1994-95, Tromsø 5; 2001-2, and/or Tromsø 6; 2007-8). The fourth 
survey is the largest one, and all inhabitants of the Tromsø municipality aged above 24 years 
were invited. In Tromsø 5 and 6 only subgroups of the municipality of Tromsø were invited. 
The overall attendance rate was high, ranging from 77% in Tromsø 4 to 66% in Tromsø 6, 
and the age and gender distribution of the study population is similar to other Western 
populations in terms of the incidence and prevalence of risk factor distribution. The VTE 
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incidence found in our population is also comparable to other Western populations6, 25, 163, 
contributing to the external validity of our findings. However, a lower attendance rate was 
noted for younger (<35 years) and older (≥80 years) subjects, as well as in men199, threatening 
the generalizability toward these subgroups. Comparison of socioeconomic status and 
mortality rates between attendees and non-responders in population-based surveys have 
shown lower socioeconomic status and higher mortality among non-responders204, 205. 
According to Langhammer et al., the most important reason for non-participation in 30-year-
old subjects is lack of time or an inconvenient time for appointment, whereas among 80-year-
olds, one-fifth of the non-participation is explained by illness205.  
 
5.1.3. Confounding and potential mediation  
In terms of epidemiology, a confounding factor is causally related to the outcome variable and 
correlated with the exposure in the study population, but it is not an intermediate or a result of 
either the exposure or the outcome206. In cohort studies, properties other than the exposure 
variable of interest may be unevenly distributed between the groups being compared and 
thereby confound the association between exposure and outcome. Confounding may bias the 
results in either directions; both over- and underestimate the actual effect, as well as change 
the apparent direction of an effect206. 
   Restriction of study participants is known to be one of the most effective strategies to 
deal with confounding207. For example, by restricting the analysis to women or men only sex 
imbalances cannot confound the study findings. Unfortunately, such analyses will lower the 
external validity. Another simple method is to stratify for confounders by dividing the sample 
into subgroups or strata based on characteristics thought to confound the analysis. However, 
both restriction and stratification may result in unacceptably low statistical power. Matching 
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the comparison groups is also a way to deal with confounding. However, by selecting controls 
with characteristics homogenous to those of the cases, one may introduce selection bias if the 
controls are unrepresentative of the particular population. In all papers of this thesis, 
confounders were included as covariates in multivariable regression models. Multivariable 
regression analysis secures that each exposure is not confounded by the other exposures, and 
is the most common method for reducing confounding in observational studies208. The overall 
strongest confounders in the populations were age and gender. In paper 1 and 3, age was 
adjusted for in a multivariable model, whereas in paper 2 and 4 age was used as time-scale in 
the regression analyses in order to eliminate confounding by age in a more proper way than 
the standard adjustment in a multivariable model209. In paper 1, also BMI turned out to be a 
strong confounder, and when adjusting for BMI in the age-and gender adjusted analysis the 
association observed between HbA1c and risk of VTE (HR 1.67; 95% CI 1.01-2.74) was 
highly attenuated and lost statistical significance (HR 1.27; 95% CI 0.72-2.26). Abdominal 
obesity has previously been shown to be the main contributing risk factor for VTE among 
persons with metabolic syndrome161, and the prevalence of insulin resistance is increased in 
obese individuals210 and improves with weight loss211-213. Furthermore, Schouwenburg et al 
showed that insulin resistance was not associated with risk of VTE after adjustment for BMI 
in a population-based cohort214. High BMI in patients with DM may therefore have 
confounded the previous observed association between DM and VTE.  We did also adjust for 
BMI in paper 2 as BMI is a well-established risk factor for VTE, and in non-smokers there is 
a positive association between serum TSH and BMI215. However, as the distribution of BMI is 
balanced between the comparison groups (i.e. subgroups of TSH), BMI will not have a 
confounding effect. This corroborate the no effect on risk estimates when adjusting for BMI 
in the multivariate analysis. Despite adjustment for potential confounders in prospective 
cohorts, one can never rule out the possibility of residual confounding. Unknown 
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confounders, imprecise definitions of potential confounders or insufficient data about 
potential confounders may all be a source of residual confounding. For instance, baseline 
information on inherited thrombophilic disorders were not available in the Tromsø study. 
However, information on inherited thrombophilias was collected at the time of VTE 
diagnosis. Only 16% of those with an unprovoked event had a known thrombophilic factor 
registered, suggesting that the majority of unprovoked events were caused by other risk 
factors. To the very best of our knowledge, we are not aware of any association between 
inherited thrombophilia and the exposures present in paper I-IV. Hence, we do not suspect 
inherited thrombophilias to be unrecognized confounders in our studies. 
In paper 4, subjects with high levels of both calcium and PTH had increased risk of 
VTE. This association could potentially be explained by more frequent incident of MI, 
ischemic stroke or cancer among subjects with high PTH and calcium. Recent meta-analyses 
have demonstrated an increased risk of future arterial CVD in subjects with increased PTH 
and calcium196, 197, and growing evidence support an association between MI, stroke and 
future VTE122-125. Furthermore, hypercalcemia is relatively common in patients with 
cancer216, and cancer is a well-known risk factor for VTE. We therefore examined the effect 
of high PTH and calcium on VTE risk while eliminating the potential effect of MI, stroke and 
cancer on VTE risk by performing a cause specific analysis, and the association remained 
essentially unchanged. These findings suggest that intermediate development of arterial CVD 
and cancer had minor impact on the association between high levels of calcium and PTH and 
VTE risk. 
 
5.1.4. Information bias and misclassification  
Self-administered questionnaires are frequently used to collect information on large study 
populations, generally running a risk of information bias due to misclassification. This type of 
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bias takes place when the collection of information is faulty or variables are imperfectly 
defined, potentially leading to differential (related to the occurrence of the outcome variable) 
or non-differential (not related to the occurrence of the outcome variable) misclassification 
217. The first one will most likely either lead to over- or underestimation of the true 
association, while the latter one may attenuate the true association towards the no-effect 
value. In a prospective cohort study, exposure variables are measured before the disease 
actually occurs, and consequently exposure misclassification is typically non-differential. 
Nevertheless, there are many advantages in using self-administered questionnaires, especially 
when gathering data from large study populations. It is less expensive and time consuming 
than most other methods, and some studies have actually concluded that self-administered 
questionnaires have a higher degree of validity and accuracy218, 219. For instance, a 
questionnaire may be more accurate in collecting data on sensitive and embarrassing topics 
(e.g. mental health, sexuality and alcohol use) compared to interviewer-administered 
questionnaires. 
In paper 1, misclassification in the variable of self-reported DM may have occurred. The 
prevalence of DM (type 2) is reported to be approximately 10% in western countries, and the 
prevalence is increasing220. The prevalence of self-reported DM ranging from 2% in Tromsø 4 
to 5% in Tromsø 6 is lower than expected, and likely an underestimate of the true population 
prevalence. To deal with this issue, data on self-reported DM was supplemented with data on 
confirmed DM from the MI registry of the Tromsø Study. As fasting glucose levels were not 
available, subjects with non-fasting glucose levels equal to or above 11.1 mmol/L and 
subjects with HbA1c equal to or above 6.5% were classified as having DM in accordance 
with the WHO report154. In a systematic review of primary cross-sectional studies, no 
evidence was found for fasting plasma glucose to be superior to HbA1c in screening for DM 
or impaired glucose tolerance (IGT)221.  
46 
 
Measurements of ionized calcium and albumin were not available in our study, and 
therefore we used total serum calcium (paper 4). Total serum calcium will not only reflect the 
calcium physiology, but also be a function of the serum albumin level. Finally, the serum 
samples from 1994 had been stored frozen at -70 degrees for many years before analysis and 
there appeared to have been some degradation of PTH during storage as described in a 
previous publication from the Tromsø study222. However, a strong correlation between serum 
PTH values from 1994 and 2001 do indicate that the degradation was similar in all samples222, 
and if there was an uneven degradation, this would most likely mask rather than introduce an 
association between PTH and VTE. 
Serum levels of 25(OH)D used in paper 3, were artificially measured 15-20% higher in 
smokers than in non-smokers223. However, separate analyses for smokers and non-smokers 
did not change the risk estimates. 
  
5.1.5. Modifiable risk factors  
Modifiable risk factors is a potential limitation of cohort studies, especially when information 
on exposure is only obtained once and time-lapse between exposure and disease manifestation 
is long. In the papers of this thesis, median follow-up time varied between 7.1 years and 15.0 
years, and all exposures were modifiable. In paper 3, serum levels of vitamin D were only 
measured at baseline, and as the median follow-up was 10.7 years in this study, the 
participants’ individual risk profile may have changed during follow-up, potentially leading to 
an underestimation of associations due to regression dilution bias224. Hence, the possibility of 
finding false positive associations (type I errors) decreases, whereas the risk of false negative 
associations (type II errors) increases224. In paper 2, it is likely to assume that subjects with 
low levels of TSH (<0.05 mU/ml) are detected and treated at an early stage of the disease 
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since overt hyperthyroidism most often have classical troublesome symptoms. This could also 
lead to regression dilution bias as the treatment of overt hyperthyroidism modifies the levels 
of TSH. In order to minimize a potential regression dilution effect, repeated measurements of 
participant characteristics during follow-up (paper 1, 2 and 4) allowed for changes in risk 
factors over time. In paper 1, subjects who attended more than one visit were included in a 
separate cox-regression model wherein HbA1c was entered as a time-varying covariate with 
multiple records per individual. If a subject had only two repeated measures, the last HbA1c 
value was carried forward until a new value was obtained. The results of this time-dependent 
analyses were similar to those using baseline measures only. In paper 2 and 4, we used a time-
varying analysis that included all participants, and those individuals who were re-measured 
got their exposure variable updated over time by contributing with additional observational 
periods. For instance, a person participating in Tromsø 4 could potentially contribute with two 
or three observational periods if the exposure variable also was measured in Tromsø 5 or 6, 
respectively, and no VTE occurred between the respective surveys. 
 
5.1.6. Missing values 
Missing data is a matter of concern in most studies, especially in large cohorts. Study 
participants may not complete the entire questionnaire, they may be lost to follow-up, some 
laboratory samples may be missing because of equipment failure, or the samples may be lost 
in transit or are technically unsatisfactory. Several methods exists on how to deal with missing 
data. One option is to omit variables which have many missing values, or one could omit 
individuals who do not have complete data (list-wise deletion/available case analysis)225. One 
could also in statistical analyses exclude data on subjects where the missing information is 
needed (pair-wise deletion)226. List-wise deletion is probably the most common method. 
However, by simple deleting individuals the statistical power may get unacceptable low, 
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besides the results could become biased if the number of excluded participants is high and 
differ significantly from the ones included (i.e. the observation needs to be missing 
completely at random). Another way is to use imputation techniques to replace missing 
values225. Unfortunately, none of the methods are fully satisfactory.  
   The main exposures in this thesis were not self-reported (i.e. HbA1c, TSH, Vitamin D, 
calcium and PTH), and missing values were therefore assumed to be random. Furthermore, in 
respect of clinically relevant parameters, subjects with missing values were similar to the 
subjects included in the analyses. Thus, the missing status in all papers was most likely 
completely random, and subjects without complete data of interest were therefore omitted in 
all papers (list-wise deletion). For instance, in paper 1 and 2, subjects with missing HbA1c 
and TSH values, respectively, in all three surveys (n=1560 and 890, respectively), were 
excluded from the study population. As the study population of paper 1 and 2 is of 16 156 and 
18 080 subjects, respectively, the deletion did not affect the results. However, in paper 3, the 
analytical sensitivity for serum 25(OH)D was 10 nmol/l, and five subjects had 25(OH)D 
below the detection limit. Their values were set to 5 nmol/l. Finally, subjects with missing 
values in other covariates were only omitted in the relevant statistical analyses (pair-wise 
deletion). 
 
5.1.7. Study power 
In regard to proper interpretation of risk estimates, sufficient statistical power is of critical 
importance. Power is directly related to effect size, number of outcomes and significance 
level, and an increase in either one of these measures will increase statistical power. If the 
power of a study is relatively high and a statistically significant effect is not observed, this 
implies that the effect, if any, is minor. In paper 2, our study provided 80% statistical power 
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for assessing a HR of 1.12 for VTE by increasing levels of TSH. However, we only had 5% 
statistical power to detect a 2.16 fold increased risk of VTE in subjects within the lowest 
category of TSH (<0.05mIU/L, i.e. overt hyperthyroidism) comprising only 41 VTE events. 
Consequently, there was a 95% probability of type II error (i.e. false negative finding). With a 
prevalence of overt hyperthyroidism by 0.2% in our study population we would have needed a 
cohort of approximately 550 000 subjects to detect a HR of 2.0 with 80% statistical power. 
Lack of statistical power was also a concern in paper 3, wherein our findings did not apply to 
subjects with vitamin D deficiency (<30 nmol/L) due to few VTE events among these 
subjects. 
 
5.1.8. Detection and validation of outcome 
All incident VTE events in our study were detected from the hospital discharge diagnosis 
registry, the autopsy registry, and the radiology procedure registry at the University Hospital 
of North Norway. By searching all three registries there was a higher chance of a complete 
VTE registry in case of coding errors in one of the registries. In addition, the hospital is the 
single provider of specialized health care services in the region, enhancing the completion of 
the VTE register even more. However, one cannot rule out that some VTEs may have been 
missed if they were diagnosed and treated elsewhere. In order to minimize the chance of 
misclassification, an episode of VTE was verified and recorded as a validated outcome when 
all the criteria listed in the section of methods were fulfilled.  
   Despite the use of strict validation criteria, misclassification in registration of VTEs 
cannot be completely ruled out. Retrospective registration of events depend on valid and 
complete information, therefore insufficient information in patient records may result in 
inaccuracy. Additionally, in the medical records the physician`s classification of events as 
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unprovoked or provoked were not based on any standardized instructions. However, the 
personnel registering the VTE events were blinded to the baseline characteristics, so any 
misclassification of VTEs was most likely non-differential. Unfortunately, information on 
VTE prior to baseline was not available for the study participants who did not experience 
VTE during follow-up. Thus, there is a possibility that subjects with former VTE, who should 
have been excluded from the analysis, might have been included and treated as healthy 
participants during follow-up. However, this would presumably have insignificant effects on 




















5.2 Discussion of main results  
 
5.2.1. Hyperglycemia and subsequent diabetes mellitus and risk of venous thromboembolism 
Among the studies examining the impact of hyperglycemia and subsequent DM on VTE risk, 
some studies have reported an increased risk80, 155-159, while others have failed to find an 
association135, 160-165. In the present study (paper 1), we did not find HbA1c to be a risk factor 
for future development of VTE, neither by a continuous nor by a categorical approach. 
Furthermore, HbA1c showed no significant association with either unprovoked or provoked 
VTE in subgroup analyses. 
Contrary to our findings, a case-control study158 by Hermanides et al. reported a 2-fold 
increased risk of VTE in subjects with hyperglycemia, independently of known DM. 
However, as non-fasting glucose levels were measured at the time of a DVT diagnosis158, 
inflammatory and counter-regulatory hormone action initiated by the VTE event itself may 
have caused increased glucose levels in DVT patients165. A case-control study 165 replicating 
the findings of Hermanides et al. reported no significant association between increased 
glucose levels and risk of VTE after adjusting for C-reactive protein (CRP). Nonetheless, in a 
retrospective population-based cohort by Petrauskiene et al.157, diabetic patients had about 
two-fold higher risk of VTE than non-diabetic subjects. However, no adjustments for BMI 
were made. In a previous publication from our research group, abdominal obesity was found 
to be the main contributing risk factor for VTE in subjects with metabolic syndrome161. 
Furthermore, the prevalence of insulin resistance is raised in obese subjects210 and decreases 
with weight loss211-213, and a population-based cohort study reported that insulin resistance 
was not associated with risk of VTE after adjustment for BMI214. Thus, high BMI in patients 
with DM may have confounded the observed link regarding VTE risk. This notion 
corroborates our finding where an association between HbA1c and VTE fully disappeared 
after adjustment for BMI. In contrast to our findings, the Iowa Women`s Health Study155 
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reported an association between DM and VTE even after adjustment for BMI. BMI may have 
been underestimated in this study due to self-reported data on weight and height, thus the true 
confounding effect of BMI could be attenuated.  
In the LITE study80, which combined information from two prospective cohorts (the 
ARIC study and the CHS), DM (defined as fasting glucose >7 mmol/L or non-fasting glucose 
>11.1 mmol/L) was found to be associated with a 46% increased risk of provoked VTE (95% 
CI 1.03-2.05), but not with unprovoked VTE. A 2012 ARIC paper that updated DM status 
through follow-up164 found no statistically significant association between DM and VTE. The 
discrepancy between these two studies could be due to differences in study populations, and 
the fact that Wattanakit et al164 used a time-varying analysis and had longer follow-up time. 
Besides, the finding of an association between DM and provoked VTE only, do question 
whether the previous observed association between DM and VTE is explained by other 
provoking factors and not by DM itself. This is in accordance with our findings of a tendency 
of increased risk for provoked VTE in subjects with HbA1c levels of 6.5% or more. In a case-
control study by Heit et al160, the observed link between DM and VTE was explained by more 
frequent hospitalizations of persons with DM. Hence, hyperglycemia may predispose for VTE 
through provoking factors such as arterial cardiovascular events, immobilization or infections. 
In the retrospective cohort by Petrauskiene et al.157, the frequency of coronary heart disease 
and congestive heart failure was significantly higher in the group of diabetic subjects 
compared to the group of non-diabetics, thus provoking factors such as arterial cardiovascular 
events and immobilization may also partly explain their positive finding between DM and 
VTE risk. In a more recent ARIC report from 2013156, Bell et al suggests that a diagnosis of 
DM combined with high levels of HbA1c (≥7.00%) may increase the risk of unprovoked VTE 
a 3-fold. However, the result should be interpreted with caution as this subgroup had few VTE 
events. In persons diagnosed without DM no relationship between HbA1c and VTE risk was 
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found156. In accordance to our observation, adjustment for adiposity (BMI and waist-to-hip 
ratio) lowered the HRs, suggesting that obesity is a more important contributor to VTE risk in 
subjects with hyperglycemia. This notion is further supported by three recent meta-analyses 
demonstrating that the increased risk of VTE associated with DM mainly results from 
confounders such as BMI rather than an intrinsic effect of DM on venous thrombotic risk227-
229. Finally, a recent retrospective cohort study found blood glucose as a marker of VTE in 
non-diabetic critically ill children230. However, there is no information on whether the glucose 
is measured in a fasting or non-fasting state and no adjustments for BMI were performed. 
Besides, the increased glucose levels may be caused by the VTE event itself.  
 
5.2.2. Thyroid function and risk of venous thromboembolism  
Thyroid hormones are the main regulators of metabolism, and TSH is known as the most 
sensitive measure of thyroid function. A hypercoagulable state has been linked to both 
hyperthyroidism171, 172 and subclinical as well as overt moderate hypothyroidism173-175. 
Furthermore, a relationship between thyroid disease and CVD has been reported176, 177. A 
registry-based study178 of 19 519 000 subjects reported a 1.6-fold increased risk of VTE in 
hypothyroid patients identified by diagnosis codes, but no association was found between 
hyperthyroidism and VTE. Unfortunately, information on time between the diagnosis of 
thyroid dysfunction and the VTE event was lacking, and no data was available on the degree 
of thyroid dysfunction, the number of patients on thyroid hormone replacement therapy and 
confounders such as BMI. In contrast, a case-cohort study179 found a 2-fold increased risk of 
PE in hyperthyroid patients. However, adjustment for potential confounders such as BMI 
were lacking, and the diagnosis codes were identified from an administrative database and not 
directly from medical records. Nonetheless, a case-control study180 and a nested case-control 
study181 found an increased risk of VTE in persons with FT4 levels within the upper local 
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reference range, and in the nested case-control study181 a non-significant OR of 1.3 was 
observed in the lower 2nd percentile of TSH (<0.37 mU/L). The analyses of the case-control 
study180 were limited to a population with DVT, and as blood was drawn at the time of 
thrombosis, the FT4 levels could potentially have been influenced by the thrombotic event 
itself. In the nested case-control study181 blood was sampled only once and the time between 
blood sampling and measurement of thyroid parameters was about 12 years. Thus, as thyroid 
parameters are modifiable they might not reflect the actual level at the time of thrombosis.  
In order to minimize regression dilution effect, we performed a time-varying analysis 
(paper II), which allowed for changes in TSH over follow-up in subjects who were measured 
more than once. We found that TSH within the normal range was not associated with risk of 
VTE. However, we observed a moderately higher risk of VTE in subjects with low 
(prevalence: 0.22%) and high (2.58%) TSH levels compared to subjects with normal TSH, but 
the confidence intervals were wide due to low number of subjects in these subgroups. 
Furthermore, the share of events among the general population that can be explained by 
thyroid dysfunction (i.e. both increased and decreased TSH levels) was low (PAR 4%). 
Unfortunately, data on FT4 was not available in our study, and the potential relationship 
between levels of FT4 and VTE risk could therefore not be explored. However, third 
generation assays of serum TSH, as we have used in our study, is usually considered the most 
sensitive measure for diagnosing hyper- and hypothyroidism168.  
In agreement with previous findings linking both hyperthyroidism and subclinical- and 
overt hypothyroidism to a hypercoagulable state171-173, 178, 231-234, we observed an apparently 
U-shaped association between TSH levels and risk of VTE. A 2-fold increased risk of VTE 
was observed in subjects with low TSH compared to subjects with normal TSH. This finding 
is in accordance with the previous case-control and nested case-cohort studies180, 181, reporting 
an association between high normal levels of FT4 and VTE risk. In contrast, a recent 
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prospective multicenter cohort235 of an elderly population found that subclinical 
hyperthyroidism (TSH<0.45 mU/L and normal FT4 levels) was associated with lower risk of 
VTE. However, they only investigated the risk of recurrent VTE the initial two years after 
incident VTE. Besides, due to few events among subjects with subclinical hyperthyroidism, 
this finding could be random. Another theory explaining the U-shaped association observed in 
our study is that thyroid dysfunction (i.e. both high and low TSH) may predispose for VTE 
through other factors such as associated hospitalization or co-morbidities. This is supported 
by the observed association between thyroid dysfunction and provoked VTE in our study, 
implying that factors other than TSH and thyroid hormones could play an important role in 
the risk assessment of VTE among subjects with thyroid dysfunction. 
 
5.2.3. Vitamin D and risk of venous thromboembolism 
Vitamin D status is most reliably determined by serum levels of 25(OH)D as it integrates 
vitamin D derived from endogenous production and dietary intake184. Previous experimental 
studies have suggested antithrombotic properties for vitamin D and observational data have 
supported the hypothesis of an inverse association between serum vitamin D concentration 
and VTE risk. In the present study, we found that serum levels of 25(OH)D were not 
associated with future risk of VTE (paper 3). Our findings were consistent regardless of 
whether vitamin D was investigated by using a categorical or a continuous approach. 
Furthermore, no associations were revealed between vitamin D and unprovoked or provoked 
VTE.  
The Swedish MISS (Melanoma Inquiry of Southern Sweden) study, including 40 000 
women aged 25-64 years with 11 years of follow-up, concluded that women with more active 
sun exposure habits had a 30% reduced risk of VTE and that the incidence of VTE was 50% 
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lower during the summer season190. They questioned whether both phenomena were mediated 
through higher vitamin D levels190. This is in conflict with our findings. However, the reduced 
risk of VTE among women with active sun exposure habits may be mediated by some 
unrecognized confounders. Furthermore, a seasonal variation of VTE incidence rates have 
been reported since 1939, and in a multicenter study on consecutive case series from Leiden, 
Milan and Tromsø236 the lowest prevalence of VTE was noted in spring. However, the 
absolute difference in risk in spring as compared with the other seasons was small (2%) and 
without any clinical relevance236. Furthermore, levels of serum 25(OH)D are known to vary 
greatly with sun exposure. In Tromsø, one would therefore expect a significant seasonal 
variation of vitamin D status due to the tremendously seasonal variation in UV exposure. 
However, due to the generally high dietary intake of vitamin D provided by fish meals and 
fish oil supplementation in the Tromsø population, especially in winter, the seasonal variation 
in serum 25(OH)D status is diluted237. Nonetheless, in order to control for seasonal variation 
in our study, intra-monthly vitamin D quartiles were used in the analyses. Contrary to our 
finding, a report from the Copenhagen City Heart cohort and the Copenhagen General 
Population cohort238 found a weak inverse association between 25(OH)D level and VTE after 
controlling for seasonal variation. However, in the samples from the Copenhagen City Heart 
Study there could have been some degradation of vitamin D during storage at –20°C. 
Furthermore, misclassification of VTE events may have occurred as some of the events were 
based on clinical suspicion only. Though, such misclassification would probably be non-
differential, and therefore bias the results toward the null finding. In accordance to our 
findings, a population-based cohort study239 and a recent case-control study in elderly 
patients240 found no association between seasonally adjusted serum 25(OH)D and VTE risk. 
Some prospective studies have reported that subjects with serum 25(OH)D levels 
below 30 nmol/l have increased risk of CVD189, 241, and a recent case-control study242 on an 
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Iranian population reported that low levels of 25(OH)D were associated with unprovoked 
DVT. In our study, we observed an increased risk of VTE in subjects with serum 25(OH)D 
deficiency (<30 nmol/l) compared to those with normal serum 25(OH)D levels, but the 
finding was not statistical significant. In the ARIC paper by Folsom and colleagues239, a meta-
analysis was performed of the HRs of 1.28, 1.32 and 1.14 for the highest vs. lowest 25 (OH)D 
categories in the Copenhagen238, Tromsø (the present study) and ARIC239 studies, resulting in 
a pooled HR of 1.25 (95% CI 1.07–1.45), and no evidence of between-study heterogeneity 
was observed. This finding suggests that low 25(OH)D levels could be associated with a 
modestly increased VTE risk. Finally, a post-hoc analysis from The Women’s Health 
Initiative (WHI) Trial, reported nearly 40% reduced risk of unprovoked VTE in 
postmenopausal women randomized to calcium + vitamin D supplementation198. However, 
the unprovoked VTE events were limited and there was no association with overall risk of 
VTE. The inconsistency between the previous studies may to some extent rely on individual 
variations in outdoor exposure time, sun exposure, dietary vitamin D intake/supplements, and 
skin pigmentation243, 244.  
                                                                                                                                              
 5.2.4. Calcium and parathyroid hormones and risk of venous thromboembolism  
Calcium is an essential co-factor in the coagulation cascade, and several studies have shown 
associations between calcium, PTH and concentrations of hemostatic factors and coagulation 
activators193-195, suggesting that high calcium and PTH causes an imbalance in the hemostatic 
system in an unfavorable prothrombotic direction. In the present study (paper 4), we found 
that neither increased serum levels of PTH nor total serum calcium was associated with future 
risk of total VTE or VTE subtypes. While our study is the first population-based study to 
investigate an impact of serum levels of calcium and PTH on VTE risk, supplementation with 
calcium and vitamin D have been explored as a possible risk factor for VTE in a RCT among 
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postmenopausal women198 demonstrating that 7 years of daily supplementation with calcium 
and vitamin D had no effect on overall VTE risk. In contrast, recent meta-analyses of 
prospective studies have reported that serum calcium245 and PTH246 were significantly 
associated with risk of arterial CVD. Arterial CVD was associated with a HR of 1.08 by one 
standard deviation increase in serum calcium, and the risk estimate remained essentially 
unchanged after adjustment for atherosclerotic risk factors245. Furthermore, subjects in the 
highest quartile of serum PTH had 45% increased risk of arterial CVD than subjects within 
the lowest PTH quartile246. In our study, we found however that discordant high serum levels 
of both PTH and total calcium were associated with a 78% increase of VTE risk independent 
of age, sex and BMI. The effect could potentially be mediated by indirect (e.g. influence of 
atherosclerotic risk factors and arterial cardiovascular diseases) or direct prothrombotic  
mechanisms (e.g. prothrombotic imbalance of the hemostatic system). 
In accordance with previous studies197, 247, 248, we found that high levels of serum 
calcium and PTH was associated with an unfavorable profile of some atherosclerotic risk 
factors such as high blood pressure, and high total cholesterol and triglycerides. Results from 
prospective cohorts have revealed that of atherosclerotic risk factors only age, obesity and a 
family history of MI are shared risk factors for arterial CVD and VTE26, 134-136, 229. Thus, it is 
unlikely that atherosclerotic risk factors could explain the association between high levels of 
serum calcium, PTH and VTE risk found in our study.  
Observational studies have found a transient association between MI, stroke and future 
risk of VTE in the general population122-125. The transient increase in VTE risk after MI and 
stroke may in the recovery phase partly be explained by indirect causal factors including 
hospitalization, immobilization and complications such as infections, which are strong 
predisposing factors for VTE105. Nonetheless, direct causal mechanisms secondary to local 
disturbances in the cardiopulmonary circulation or electromechanical pathway (e.g. atrial 
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fibrillation) may also contribute to the VTE risk observed in MI patients124. Additionally, 
hypercalcemia is relatively common in patients with cancer, and cancer is a well-known risk 
factor for VTE. However, the effect of discordant high levels of PTH and calcium on VTE 
risk in our study remained essentially unchanged after censoring for MI, stroke and cancer in 
a cause-specific model, implying that the apparent VTE risk by high levels of calcium and 
PTH is not mediated by arterial cardiovascular diseases (e.g. stroke and MI) or cancer.  
Based on the limited existing literature and our present findings, serum levels of 
calcium and PTH alone do not appear to be independently associated with VTE. However, in 
our population-based study, discordant high serum levels of both PTH and calcium was 


















6. CONCLUSIONS  
 
 In our study, serum levels of HbA1c were not significantly associated with future risk 
of VTE after adjustment for BMI. Our findings suggest that hyperglycemia does not 
play an important role in the pathogenesis of VTE, and that obesity is a more 
important contributor to VTE in subjects with hyperglycemia. 
 
 We found no association between serum levels of TSH within the normal range and 
future risk of VTE. However, low and high TSH levels were rare and associated with a 
moderate higher risk of VTE. Nevertheless, the low prevalence of thyroid dysfunction 
and the low PAR%, imply that only a minor proportion of the VTE events in the 
general population may be attributed to thyroid dysfunction. 
 
 Serum levels of 25(OH)D were not associated with future risk of VTE, suggesting that 
vitamin D status does not play an important role in the pathogenesis of VTE.  
However, our findings did not apply to subjects with vitamin D deficiency (< 30 
nmol/L) due to lack of statistical power among these subjects. 
 
 Serum levels of calcium and PTH were not associated with future risk of VTE. 
However, subjects with high levels of both calcium and PTH had increased risk of 







7. FINAL REMARKS AND FUTURE PERSPECTIVES 
The current knowledge concerning the association between endocrine-related factors (e.g. 
HbA1c, TSH, vitamin D, calcium and PTH) and risk of VTE is limited, and previous studies 
have reported diverging results. Based on the findings of our present studies, HbA1c, TSH, 
vitamin D, calcium and PTH do not appear to be individually associated with VTE risk. 
Previous studies investigating an association between these factors and VTE risk, ought to be 
carefully considered in respect of methodological differences (e.g. study design, study 
population, number of VTE events, provoking factors and unrecognized confounders). 
In order to come closer to a conclusion on whether the incidence of VTE is related to 
blood glucose levels, the VTE incidence may be assessed as a secondary endpoint in diabetic 
subjects participating in RCTs aiming to improve blood glucose levels. Regarding thyroid 
function and VTE risk, it would be interesting to explore levels of FT4 as a risk factor for 
VTE within a population-based cohort as increased FT4 levels are associated with VTE risk 
in case-control studies. Furthermore, the incidence of VTE could be assessed as a secondary 
endpoint in hypo- or hyperthyroid patients participating in RCTs aiming to improve thyroid 
function. In order to reach a conclusion on the impact of vitamin D deficiency on risk of VTE, 
examination of VTE as an outcome in ongoing vitamin D supplementation trials is warranted. 
Although serum levels of calcium and PTH alone did not appear to be individually 
associated with VTE risk in our study, we observed that high serum levels of both PTH and 
calcium were associated with increased VTE risk even after eliminating the potential effect of 
MI, stroke and cancer on VTE risk. As we are the first to investigate the associations between 
serum levels of calcium, PTH and future risk of VTE in a general population, further 
population-based studies are needed. Furthermore, the VTE incidence could be assessed as a 
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